Contents

Volume 94 Issue 1 | JNNP January 2023

Multiple sclerosis

1  Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis
X Montalvo, D Wallace, M C Genovese, D Tomic, D Parsons-Rich, C Le Bolay, A H Kao, H Guebing

10  Spinal cord lesions and brain grey matter atrophy independently predict clinical worsening in definite multiple sclerosis: a 5-year, multicentre study

19  Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations

23  Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network

31  Brain age gap in neuromyelitis optica spectrum disorders and multiple sclerosis
R Wei, X Xu, Y Duan, N Zhang, J Sun, H Li, Y Li, Y Li, C Zeng, X Han, F Zhou, M Huang, R Li, Z Zhuo, F Barkhof, J H Cole, Y Liu

38  Safety of breast feeding during rituximab treatment in multiple sclerosis
B E Red, O Torkildsen, K-M Myhr, L Be, S Wergeland

Epilepsy

42  Levitiracetam versus fosphenytoin as a second-line treatment after diazepam for adult convulsive status epilepticus: a multicentre non-inferiority randomised control trial
K Nakamura, A Marusuma, Y Tatehashi, M Machizuki, A Kimura, Y Yokoda, M Asami, H Nakamoto, S Egawa, J Kando, K Unemoto, Y Kondo, C Yonekawa, M Uchida, E Hoshiyama, T Yamada, K Maruo, E Ishikawa, Y Matsushima, Y Hase, JNEC ECT with the LIFE study group

Neurosurgery

49  Short-lasting unilateral neuralgiform headache attacks (SUNCT/SUNA): a narrative review of interventional therapies
R D Omde, N Mou besten, K C Kang, M Reyes, A Sathe, S Collropy, G Peashant, H Yuan, J J Evans

Disclaimer: The Editor of JNNP has been granted editorial freedom and JNNP is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. JNNP is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any warranty as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by JNNP does not imply endorsement. BMJ Publishing Group Limited shall not be liable for any loss, injury or damage howsoever arising from JNNP (except for liability which cannot be legally excluded).

Copyright: © 2023 BMJ Publishing Group Ltd. All rights reserved; no part of this publication may be reproduced in any form without permission.

JNNP is published by BMJ Publishing Group Ltd., BMA House, Tavistock Square, London WC1H 9JR UK.
Printed in the UK on acid-free paper from sustainable forests.
Journal of Neurology Neurosurgery & Psychiatry (ISSN 0022-3256) (UPDS 2106) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London, through an agent named World Container Inc., 150-15, 18th Street, 4th, New York, NY, USA, Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: send address changes to Journal of Neurology Neurosurgery & Psychiatry, World Container Inc., 150-15, 18th Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London Air Business Ltd is acting as our mailing agent.
Neuro-inflammation
57  Association of obesity with disease outcome in multiple sclerosis
   ILutfullin, MEveslage, SBittner, GAntony,
   MFlaskamp, FLuessi, SAubner, BGisevius,
   LKlotz, CKorsukewitz, ABertele, SGroppa,
   FTheinBergh, BWildemann, ABayas, HTumann,
   SGMeuth, CTrebst, UKZeitl, FPaul, CHHeesen,
   TVioumpel, RGold, BHemmert, FZipp, HWiendt,
   JDLüsemann, on behalf of the German Competence
   Network Multiple Sclerosis (KKNMS)

62  Efficacy and safety of rituximab in myelin
   oligodendrocyte glycoprotein antibody-
   associated disorders compared with
   neuromyelitis optica spectrum disorder: a
   systematic review and meta-analysis
   GSpagni, BSun, GMonte, ESechi, Rlono,
   AEvol, VDamato

Cerebrovascular disease
70  Circadian rhythm of ischaemic core progression
   in human stroke
   PReidler, ABrehm, PBSporns, VGBurhan,
   LStueckelsweiger, GBrooks, TLietig,
   MNPsychogios, JRecke, KDimitriadis,
   MDichgans, WGKuntz, STiedt

Neurodegeneration
83  Cerebrospinal fluid β-synuclein as a
   synaptic biomarker for preclinical
   Alzheimer’s disease
   LBarba, SAbuRumeileh, GBellomo,
   FPaoliniPaolent, SHaltweghauer, POecbl,
   PSteinacker, FAlessi, LGaetani, LParnetti,
   MSOn

PostScript
87  Letters